Home

Cronică conservator Descriptiv teva financial statements Laterale excepție mat

Teva Pharmaceutical Industries Ltd. - Investors
Teva Pharmaceutical Industries Ltd. - Investors

Form 10-K
Form 10-K

Price-fixing lawsuit deals another blow to already fragile Teva, experts  say | The Times of Israel
Price-fixing lawsuit deals another blow to already fragile Teva, experts say | The Times of Israel

Teva Pharmaceuticals on X: "Teva just announced its Q2 2022 financial  results. View the press release here: https://t.co/OGECc00hWU  Forward-looking statements are subject to the cautionary note included in  our Q2 2022 press
Teva Pharmaceuticals on X: "Teva just announced its Q2 2022 financial results. View the press release here: https://t.co/OGECc00hWU Forward-looking statements are subject to the cautionary note included in our Q2 2022 press

Teva Pharmaceutical Industries Limited 2022 Q4 - Results - Earnings Call  Presentation (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Industries Limited 2022 Q4 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha

Drugmaker Teva does not see big impact on business from Israel-Hamas war |  Reuters
Drugmaker Teva does not see big impact on business from Israel-Hamas war | Reuters

Teva Completes Amendment to Credit Facilities
Teva Completes Amendment to Credit Facilities

Form 10-K
Form 10-K

Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight
Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight

DEF 14A
DEF 14A

Teva Pharmaceutical says it will defend claims it was involved in  price-fixing in the US
Teva Pharmaceutical says it will defend claims it was involved in price-fixing in the US

Closure of another criminal case will help Teva's new CEO to focus on  return to growt | Ctech
Closure of another criminal case will help Teva's new CEO to focus on return to growt | Ctech

Teva Pharmaceutical: What To Expect In 2023 With New CEO (NYSE:TEVA) |  Seeking Alpha
Teva Pharmaceutical: What To Expect In 2023 With New CEO (NYSE:TEVA) | Seeking Alpha

Investors sue Teva over $41B Actavis deal - Drug Delivery Business
Investors sue Teva over $41B Actavis deal - Drug Delivery Business

Teva Pharma Q2 Revenues Drop 18% | BioSpace
Teva Pharma Q2 Revenues Drop 18% | BioSpace

Teva Reports Fourth Quarter and Full Year 2022 Financial Results | Business  Wire
Teva Reports Fourth Quarter and Full Year 2022 Financial Results | Business Wire

Teva Pharmaceutical Industries Limited Trade Ideas — NYSE:TEVA — TradingView
Teva Pharmaceutical Industries Limited Trade Ideas — NYSE:TEVA — TradingView

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must  Consider (NYSE:TEVA) | Seeking Alpha
The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider (NYSE:TEVA) | Seeking Alpha

Net profits of Pliva, Barr, and Teva Pharmaeuticals before and after... |  Download Scientific Diagram
Net profits of Pliva, Barr, and Teva Pharmaeuticals before and after... | Download Scientific Diagram

Teva beats on Q3 revenue and raises guidance - Globes
Teva beats on Q3 revenue and raises guidance - Globes

Teva Stock Plunges On Flat Sales, Earnings Disappointment | Investor's  Business Daily
Teva Stock Plunges On Flat Sales, Earnings Disappointment | Investor's Business Daily

Teva's stunning list of cuts targets 14K jobs, $3B in costs and plants  around the globe | Fierce Pharma
Teva's stunning list of cuts targets 14K jobs, $3B in costs and plants around the globe | Fierce Pharma

Teva Pharmaceutical Industries Ltd. - Investors
Teva Pharmaceutical Industries Ltd. - Investors

DEF 14A
DEF 14A

Teva Pharmaceutical reports 5% fall in Q4 2022 revenue
Teva Pharmaceutical reports 5% fall in Q4 2022 revenue

Teva Pharmaceutical's annual financial results 2018 | Statista
Teva Pharmaceutical's annual financial results 2018 | Statista

Teva Pharmaceutical net income 2006-2023 | Statista
Teva Pharmaceutical net income 2006-2023 | Statista

DEF 14A
DEF 14A